Hemab Therapeutics Holdings, Inc. filed a Form S-1 registration statement with the US Securities and Exchange Commission for an initial public offering of common stock on Nasdaq Global Select Market under the ticker symbol "COAG." The filing did not disclose the number of shares offered, the price range, or the total gross proceeds.
Prior to the offering, Hemab Therapeutics had raised approximately USD 346.0 million from private investors including Access Biotechnology, Avoro Capital Advisors, Deep Track Capital, HealthCap, Novo Holdings, RA Capital Management, SMALLCAP World Fund, and Sofinnova.
Hemab Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for blood coagulation disorders, including Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase I/II clinical development for prophylactic treatment of Glanzmann thrombasthenia and in Phase 2 development for prophylactic treatment of Factor VII deficiency. The company stated that sutacimig has received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA, as well as an Innovative Licensing and Access Pathway designation from the UK Medicines and Healthcare products Regulatory Agency, for the Glanzmann thrombasthenia indication.
In the Phase I/II trial of sutacimig in Glanzmann thrombasthenia, the filing states that Part A established proof-of-mechanism and Part B demonstrated a reduction in mean annualized treated bleed rate ranging from 19% to 87% across all regimens tested, with a 100% reduction in mean high-intensity annualized treated bleed rate during the treatment period. The company stated it expects to commence a Phase III trial in Glanzmann thrombasthenia in the second half of 2026, with Phase II data in Factor VII deficiency anticipated in late 2026 or early 2027.